Ocrelizumab (Ocrevus®): Now also approved in the EU

Ocrelizumab (Ocrevus®): Now also approved in the EU

Ocrelizumab has now also been approved in the EU for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features.[1] This European approval in January 2018, followed two previous approvals in 2017, granted to Genentech, the developers,  initially in the US (March) [2] and later in Canada (August)[3] for the same indication. Continue reading “Ocrelizumab (Ocrevus®): Now also approved in the EU”